AVRA Surgical, Inc. was organized in 2008 to bring patient inspired medical technology into the global marketplace. They work in close cooperation with strategic partners on the commercialization of unique medically related products in the surgical arena and in the area of wireless implantable devices.
AVRA Surgical's current activities consist of developing products independently and in collaboration with their medical, academic, scientific and engineering partners.
AVRA is focused on high-quality, cutting-edge technologies for new, breakthrough medical products and services, with a strong emphasis on "Improving the patient's quality of life".
AVRA Surgical Inc. Invested In The Following Technologies:
Transcutaneous Energy and Telemetry System for Intelligent Implants (TET)
Today, transcutaneous wires in medical devices can lead to a high risk of infection. Full implantation of all components minimizes that risk of infection and improves patients' mobility and comfort. The status of the implant and patients' health can be observed as data is transmitted wirelessly and bi-directionally, including 24x7 remote monitoring of vital signs sent to doctors/hospitals.
The Dualis TET system transfers energy “wirelessly” through the skin from a transmitter coil to an implantable receiver coil by the principle of inductive coupling. Their Wireless Technology opens up new, revolutionary therapy possibilities for the growing field of implantable devices. Advanced miniaturization, improvements in implant functionality, and the need for data transfer require more energy than can be provided by current implantable batteries or bulky external batteries.
Wireless Intelligent Implants
Bi-Ventricular Assist Device (Bi-VAD)
The DLR Bi-Ventricular Assist Device consists of a novel double-chamber technology which provides relief to the heart with a physiologically favorable pulsating volume flow. There are no impellors and the blood is never churned as with the typical LVAD.
Because the Bi-VAD will be powered by the wireless energy and data transfer system (TET), the risk of infection from wires through the skin is eliminated.
Optimum relief of the heart gives cardiac patients the combination of relief if waiting for a heart transplant and for those not eligible for a heart transplant, a longer term quality of life unachievable today from the current LVADs.
The DLR Bi-VAD heart patients will "have a pulse”.
Investigational Device Only
Implantable Kidney Dialysis Device (IKDD)
AVRA Surgical, Inc., has worked with Boston Childrens Hospital in designing an Implantable Kidney Dialysis Device (IKDD) to assist those patients with kidney failure or end stage renal disease.
AVRA Surgical's IKDD is in the family of their Intelligent Implants and will offer a unique approach to dialysis patients worldwide. The prototype is expected to enter clinical trials in 2018.
This new device combines the efficiency of hemodialysis with the convenience of peritoneal dialysis. It is a 24/7 process which spares the patient constant hospital visits (3-4 visits per week at 3-5 hours per visit) and ensures that the patient has renewed freedom to live, work and travel normally.
Implantable Wireless Sphincter System (IWSS)
A Spin-off from the DLR is developing a newly designed sphincter system powered by their own Wireless Technology.
The historic and consistent high failure rate currently found in hospital procedures for existing sphincter devices has spurred the interest and investment by AVRA Surgical, in a joint development pact with US and European partners, to develop the new Implantable Wireless Sphincter System (IWSS) to aide hospitals, doctors and patients alike......stay tunedfor more information......
Image from The Urology Team, P.A.
What is an Artificial Sphincter?
Although urinary incontinence is not a life-threatening situation, it certainly affects one's lifestyle. For many it means wearing damp undergarments, diapers, having skin irritation or diaper rash. It may limit his or her physical activity, social relationships, sexual attitudes, and ability to do spontaneous activities without careful planning.
Medical therapies including medications, exercise programs, and biofeedback techniques have helped many of these patients. However, there remains a group of patients who still have leakage of urine to such a severe degree that something more than the above treatments must be done. For these people, surgical implantation of an artificial urinary sphincter may be a winning solution. Patients who have achieved success with an artificial sphincter include men who have had surgery on their prostate and have tried multiple drugs and devices with no success.
Before this device is implanted the patient must obviously have severe symptoms and have failed all other drug, biofeedback, and other surgical approaches. Their bladder must be large enough so that it can hold enough urine in-between urinating. The bladder has to be neurologically intact, not contracting on a regular basis and causing high bladder pressures, urgency, and a need for frequent urination. The bladder must also be infection free and prior to the implant the patient must be able to empty the bladder completely. If these criteria are met then the patient may be a candidate for the implantation of the artificial sphincter.
Founder and Chairman of AVRA Surgical Robotics, Inc.
and AVRA Surgical, Inc.
Mr. Cohen has been a president and a director of public companies as well as acted as CEO of his own NASD member investment firm. Currently, he has a leadership role in identifying the opportunities and benefits of robotic surgery.
For some time now, he has been closely studying and investigating how robotics is changing the surgical landscape worldwide. He has traveled extensively for many years, observing and integrating into the small and growing field of surgeons who have adopted robotic surgery as their specialty.
To promote and advance this dynamic field, allaboutroboticsurgery.com was chosen to represent "AVRA" as an unbiased central comprehensive source for news and information specific to robotic surgery and medical robotics.
HeartWare and DUALIS MedTech Announce Agreement to Develop Fully Implantable Ventricular Assist System FRAMINGHAM, Mass. and SYDNEY, Jan. 9, 2012 /PRNewswire/
HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, and Dualis MedTech GmbH today announced an agreement to develop ventricular assist devices with wireless, transcutaneous energy transfer system (TETS) technology exclusively for HeartWare.
Since mid-2011, a collaborative team of HeartWare and Dualis engineers has successfully demonstrated the feasibility of integrating Dualis' proprietary wireless energy transfer technology with the HeartWare® HVAD and MVAD systems. Under terms of the agreement, HeartWare will fund a TETS development program for left ventricular assist devices (LVADs), as well as receive an option to fund programs to explore developments in bi-ventricular support and first rights to future developments outside the field of TETS and ventricular assist devices.....read more
Any medical information published on this website is intended purely as a informational tool only and is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional.
The Copyright of all images and documents is by the According Developing Group, Institute, Editor or Company. We only included data and images freely accessible. We have linked each image and/or story back to it's original source. If you want your system or certain information on it removed from our website, please contact us at email@example.com